))
Alliance for Regenerative Medicine (ARM) State of the Industry 2024 Overview
Manage episode 446561405 series 3610310
Вміст надано TheRHA.org. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією TheRHA.org або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
In this episode of The Regenerative Health Podcast, our hosts review the 2024 State of the Industry presented by the Alliance for Regenerative Medicine at the BioTech Showcase earlier this year. At this US based industry trade gathering, the focus is on FDA approvals including the acceleration of approvals for new gene therapies for diseases such as Sickle cell, muscular dystrophy, diabetes and more. Now while it is encouraging to see the progress from the FDA, the United States continues to lag far behind other countries in research and clinical experience with regenerative health. We'll explore accelerated and exciting developments in other countries including India, Panama and Mexico in future episodes, But now, let's listen in on what the Alliance for Regenerative Medicine in the US is working on with the FDA Scientific Exchange on Building Blocks of PlatformTechnologies and expediting the development of Stem Cell and Gene Therapy.
If you'd like to learn more about stem cells and regenerative health, please visit The Regenerative Health Association at: www.therha.org.
It's the world's first and largest community for regenerative health consumers with a wealth of information and resources for you.
6 епізодів
Поширити
